Skip to content
Search

Latest Stories

Bristol Labs director PM Raju succumbs to Covid-19

The co-founder and a senior director of Bristol Laboratories, one of the country’s leading ge­neric medicine manufacturers, died last Sunday (Feb 14) after con­tracting coronavirus.

PM Raju was admitted to the Royal Brompton Hospital in Lon­don last month after his condition deteriorated following the Covid-19 infection.


He succumbed to complica­tions from the virus, having been in the intensive care unit of the hospital for a month. He was 63 and is survived by his wife, Grace, his two sons, Hanson and Benson and his daughter-in-law, Jisha.

Raju helped found Bristol Lab­oratories and played a key role in its meteoric growth over the past decade. He was a close friend and associate of T Ramachandran, the founder and chairman and managing director of the company.

The two friends started the business from a small office in Harrow, North London in 1997 and together built an enterprise spanning the UK and Europe.

RAJU AND RAMACHANDRAN T Ramachandran (L) and PM Raju

Ramachandran said: “I can never forget 40 years of unconditional partnership with him being side by side with me and my family in happiness and sorrow.

“He was a brother to me and my wife Sreedevi and a beloved uncle to my daughters. Words will never do justice for the greatness of one soul who touched the lives of everyone he met.”

Both Raju and Ramachandran formed a close association while working for several years at IPCA Laboratories – a large pharmaceutical company based in India.

In 1997, Raju moved to the UK to help Ramachandran set up Bristol Laboratories and had since been overseeing all aspects of the company’s growth as “second in command”.

In a statement, Bristol Labora­tories said, “His passion, drive and loyalty towards the business was not just a professional one but a personal commitment to serve and excel in the field.

“He was a caring father, a pas­sionate leader and always a phone call away when you need­ed him. He never said no to any­one and has left a void in our hearts forever.”

Raju was a respected and pop­ular member of British pharma industry who did much to push innovation and develop new ter­ritories for Bristol Laboratories.

A regular presence at industry events, he built strong relation­ships with wholesalers and com­munity pharmacists who came to rely on Bristol Laboratories’ ex­tensive product portfolio.

Paying tribute, CEO of Sigma Pharma­ceuticals Bharat Shah said, “I have known Raju for more than 20 years. I have seen him trans­form from an export executive in India with IPCA to becoming a very powerful executive with Bristol Labs in the UK.

“He was instrumental in devel­oping Bristol Laboratories into one of the leading generic medicine manufacturers in the UK. He would help everyone in the most polite and effective manner. He will be greatly missed not only in the ge­nerics industry in the UK, but al­so by people who knew him.”

Born in Adoor, in India's southern state of Kerala, Raju completed his graduation in commerce from Kerala University.

He was the founder and a dedicated member of the Indian Orthodox Church in Hemel Hempstead, serving as the council member of the Diocese of UK-Europe and Africa for several years.

Diocesan Bishop Dr Mathews Mar Thimothios Metropolitan of the Indian Orthodox said: “He always stood as a pillar on my right side for all my missions of the diocese.

PM raju with Bishop PM Raju with bishop outside St Michael's Church in Hamworthy, Pool on Aug 31, 2019

Raju also played an important role in helping to establish a Malayalee Christian community in North London.

A religious leader who knew Raju described how he helped members of the community.

“When people (from Kerala) landed in the UK, whoever got in touch with him would always get plenty of help – anything from finding accommodation to finding a job. This has been the case for many years,” he said.

The secretary of the Hemel Hempstead church praised Raju as a “very hard working, soft spoken person and a great role model to everyone”.

More For You

Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less
Three pharmacists named in NIHR’s latest cohort of senior investigators

L-R: Professor David Alldred; Professor Rachel Elliott and Professor Ian Maidment.

Three pharmacists appointed as NIHR senior investigators

The National Institute for Health and Care Research (NIHR) has announced its latest cohort of senior investigators, including three distinguished pharmacists.

David Alldred, professor of medicines use and safety at the University of Leeds; Rachel Elliott, professor of health economics at the University of Manchester; and Ian Maidment, professor in clinical pharmacy at Aston University, have been named in the list of 39 new appointments, alongside 19 reappointed senior investigators.

Keep ReadingShow less
Vaccine-preventable infections costing UK billions

Effective interventions are needed to prevent hospitalisations

Vaccine-preventable infections costing UK billions

Effective interventions are having a positive impact but more needs to be done to combat vaccine-preventable infections after data revealed today showed that it accounted for 20 per cent of hospital bed usage in the UK between 2023 to 2024 at a cost of almost £6 billion.

The return of social mixing, international travel and migration following the COVID-19 pandemic have contributed to the rise in both endemic disease and vaccine-preventable infections, according to the UK Health Security Agency's (UKHSA).

Keep ReadingShow less